Pfizer Inc. (NYSE:PFE) Stock Position Lowered by Capital Advisors Inc. OK

Capital Advisors Inc. OK lessened its position in Pfizer Inc. (NYSE:PFE) by 3.0% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,396,440 shares of the biopharmaceutical company’s stock after selling 43,305 shares during the quarter. Capital Advisors Inc. OK’s holdings in Pfizer were worth $37,048,000 as of its most recent filing with the SEC.

Several other large investors have also recently added to or reduced their stakes in PFE. Retirement Wealth Solutions LLC acquired a new position in Pfizer in the 4th quarter valued at approximately $26,000. Gladius Capital Management LP increased its stake in Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 38,015 shares during the period. Teachers Insurance & Annuity Association of America acquired a new position in Pfizer in the 3rd quarter valued at approximately $35,000. Joseph Group Capital Management increased its stake in Pfizer by 168.3% in the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 771 shares during the period. Finally, Sugar Maple Asset Management LLC acquired a new position in Pfizer in the 4th quarter valued at approximately $43,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE:PFE opened at $25.53 on Wednesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The business has a 50 day moving average of $26.28 and a 200 day moving average of $27.69. The company has a market capitalization of $144.69 billion, a price-to-earnings ratio of 18.11, a PEG ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business’s revenue was up 24.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.10 earnings per share. On average, sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.74%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio is presently 121.99%.

Wall Street Analyst Weigh In

Several research analysts have recently commented on PFE shares. UBS Group dropped their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Sanford C. Bernstein initiated coverage on shares of Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price target for the company. Wolfe Research started coverage on shares of Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. Finally, Citigroup dropped their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.